| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP2-25157SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB100-56874SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP1-76769SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Azide and BSA Free | NBP1-30054-0.02ml | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB110-39113SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Azide and BSA Free | NBP2-33200 | |||
| Azide and BSA Free | NBP2-33200-1mg | |||
| IHC-Prediluted | NBP2-48225 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Non-Recombinant Monoclonal | NB600-1159SS | |||
| Azide and BSA Free | NBP2-33250 | |||
| Non-Recombinant Monoclonal | NB600-1159 | |||
| BSA Free | NBP3-07012SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB100-56503SS | |||
| Azide and BSA Free | NBP2-80686 | |||
![Immunohistochemistry: mCherry Antibody [NBP2-25157] - Brn3b-mCherry expression in other regions of the CNS. Optic tracts at P0 visualized by mCherry staining (white arrows). (BAE ) Co-localization experiments with mCherry (red) and pan-Brn3 (green) antibodies at P0. (CAE ) Co-localization with mCherry (red) and Tuj1 (green) in the trigeminal ganglia at E13. 5. Arrows indicate mCherry+ Tuj+ neurons. Image collected and cropped by Citeab from the following publication (A Novel Reporter Mouse Uncovers Endogenous Brn3b Expression. Int J Mol Sci (2019)) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/mCherry-Antibody-Immunocytochemistry-Immunofluorescence-NBP2-25157-img0011.jpg "Immunohistochemistry: mCherry Antibody [NBP2-25157] - Brn3b-mCherry expression in other regions of the CNS. Optic tracts at P0 visualized by mCherry staining (white arrows). (BAE ) Co-localization experiments with mCherry (red) and pan-Brn3 (green) antibodies at P0. (CAE ) Co-localization with mCherry (red) and Tuj1 (green) in the trigeminal ganglia at E13. 5. Arrows indicate mCherry+ Tuj+ neurons. Image collected and cropped by Citeab from the following publication (A Novel Reporter Mouse Uncovers Endogenous Brn3b Expression. Int J Mol Sci (2019)) licensed under a CC-BY license.")
![Immunohistochemistry: mCherry Antibody [NBP2-25157] - Activation of TRPV1 receptors in ARC POMC neurons reduces food intake. Expression of Gi/o-DREADD in POMC neurons in the ARC (top left panel, scale bar: 20 um). Arrowheads represent POMC neurons that co-expressed mCherry (n = 493 out of 529 mCherry-positive neurons, n = 3 mice). Treatment with CNO (10 uM) hyperpolarized POMC neurons (top right panel; Control, -40.7 +/- 1.5 mV; CNO, -47.1 +/- 2.3 mV, n = 6 neurons, **p 50 measurements – 3 per cell; ***P < 0.001, one‐way ANOVA on ranks followed by Dunn's post hoc test). (C) Src‐transformed p130Cas−/−MEFs co‐expressing p130Cas (SC) & mouse Flag tagged PKN3 WT or Flag‐PKN3 mPR are shown. Cells were grown on FN‐coated coverslips for 48 h, fixed, & stained for p130Cas by anti‐pTyr165 p130Cas antibody (pY165 p130Cas; 2nd 405), for actin by Phalloidin 488 & for Flag‐PKN3 by anti‐Flag antibody (2nd 633). Reflection (670 nm) indicates fibronectin degradation. All scale bars represent 20 μm. Cell were imaged by Leica TCS SP8 microscope system equipped with Leica 63×/1.45 oil objective. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/30422386), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp2-25157_rabbit-polyclonal-mcherry-antibody-310202416114713.jpg)
![Immunocytochemistry/ Immunofluorescence: mCherry Antibody [NBP2-25157] - Brn3b-mCherry expression in the adult retina. (A) Flat-mounted retina labeled with anti-mCherry antibody. (B,B’) mCherry (red) & Brn3 (teal) colocalization. Yellow arrow indicates a Brn3+ mCherry- cell. (C,C’) mCherry (red) & RBPMS (teal) colocalization. Yellow arrows indicate RBPMS+ mCherry- cell bodies. (D,D’) mCherry (red) & Tuj1 (teal) colocalization. White arrows indicate Tuj1+ mCherry+ axons. (E–E’’’) Cross-section of an adult retina labeled with mCherry (red), RBPMS (gray), DAPI (blue), & Pax6 (green). All mCherry+ cells (white arrows) are RBPMS+. Amacrine cells are labeled with yellow stars & are mCherry- (Pax6+ RBPMS− mCherry− cells). Yellow arrowhead corresponds to an mCherry− RGC (RBPMS+ Pax6− mCherry− cell). ONH: Optic Nerve Head. ONL: Outer Nuclear Layer. INL: Inner Nuclear Layer. GCL: Ganglion Cell Layer. Scale bars: 300 microns in A, 50 microns in B–E’’’. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31197108), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp2-25157_rabbit-polyclonal-mcherry-antibody-310202416114789.jpg)
![Western Blot: Vimentin Antibody [NB300-223] - Analysis of tissue and cell lysates. Antibody at 1:5000 in red. [1] protein standard (red), [2] rat whole brain lysate, [3] HeLa, [4] SH-SY5Y, [5] HEK293, and [6] NIH-3T3 cell lysates. NB300-223 binds to the vimentin protein showing a single band at ~50 kDa. The blot was simultaneously probed with mouse mAb to MAP2C/D, dilution 1:5000 in green, revealing multiple bands around 280 kDa that correspond to full length MAP2A/2B isotypes, and ~70 kDa bands which are MAP2C/D isotypes. MAP2 isotypes are seen only in extracts containing neuronal lineage cells.](http://images.novusbio.com/fullsize/Vimentin-Antibody-Western-Blot-NB300-223-img0002.jpg "Western Blot: Vimentin Antibody [NB300-223] - Analysis of tissue and cell lysates. Antibody at 1:5000 in red. [1] protein standard (red), [2] rat whole brain lysate, [3] HeLa, [4] SH-SY5Y, [5] HEK293, and [6] NIH-3T3 cell lysates. NB300-223 binds to the vimentin protein showing a single band at ~50 kDa. The blot was simultaneously probed with mouse mAb to MAP2C/D, dilution 1:5000 in green, revealing multiple bands around 280 kDa that correspond to full length MAP2A/2B isotypes, and ~70 kDa bands which are MAP2C/D isotypes. MAP2 isotypes are seen only in extracts containing neuronal lineage cells.")
![Immunohistochemistry: Vimentin Antibody [NB300-223] - Attenuated reactive astrocytosis after stroke in Smad1 cKO mice. Enlarged IHC images of boxed areas at the cortical peri-infarct area with the indicated reactive astrocyte markers GFAP, Nestin, and Vimentin. Enlarged images of GFAP IHC highlight the hypertrophic morphology of GFAP+ astrocytes in mutants. Image collected and cropped by CiteAb from the following publication (//dx.plos.org/10.1371/journal.pone.0136967), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/Vimentin-Antibody-Immunohistochemistry-NB300-223-img0006.jpg)
![Immunocytochemistry/Immunofluorescence: Vimentin Antibody [NB300-223] - Human A7 cells. Cells were fixed with 10% formalin and permeabilized with 0.1% TritonX-100. After blocking, cells were incubated with primary antibody (1:600) at 4C O/N followed with Alexa Fluor 488 labeled secondary antibody and counterstained with DAPI and Phalloidin for nuclei and F-actin respectively. Imaged with Leica TCS SP5 confocal microscope. ICC/IF image submitted by a verified customer review.](http://images.novusbio.com/fullsize/Vimentin-Antibody-Immunocytochemistry-Immunofluorescence-NB300-223-img0004.jpg)
![Immunohistochemistry: Vimentin Antibody [NB300-223] - Increased numbers of differentiating NSPCs in SVZ of G93A-SOD1 brain. Confocal microscopy images of dorsal and ventral regions of SVZ in G93A-SOD1 and Wt-SOD1 brain at postnatal week 18, stained for nestin (green), GFAP (red), and vimentin (blue). Scale bar = 50 um. Image collected and cropped by CiteAb from the following publication (//www.molecularbrain.com/content/8/1/5), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/Vimentin-Antibody-Immunohistochemistry-NB300-223-img0007.jpg)
![Immunocytochemistry/Immunofluorescence: Vimentin Antibody [NB300-223] - Comparative analysis of epithelial and mesenchymal markers expressions. Fluorescence immunocytochemistry staining for E-cadherin (green), N-cadherin (red) and vimentin (cyan) was performed on esophageal cancer cells under static and microfluidic flow conditions at different time points. Image collected and cropped by CiteAb from the following publication (//www.nature.com/articles/srep38221), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/Vimentin-Antibody-Immunocytochemistry-Immunofluorescence-NB300-223-img0008.jpg)
![Immunocytochemistry/Immunofluorescence: Vimentin Antibody [NB300-223] - Analysis of HeLa cell culture. Antibody at 1:10,000 in green, and costained with mouse mAb to actin, dilution 1:500 in red. The blue is DAPI staining of nuclear DNA. The vimentin antibody stains the intermediate filament network while the actin antibody labels the submembranous cytoskeleton, stress fibers, and bundles of actin associated with cell adhesion sites.](http://images.novusbio.com/fullsize/Vimentin-Antibody-Immunocytochemistry-Immunofluorescence-NB300-223-img0001.jpg)
![Immunohistochemistry-Frozen: Vimentin Antibody [NB300-223] - 10 um Cryosections from PFA fixed murine brain acute slices stained with Vimentin antibody (1:600) and Alexa Fluor 488 anti chicken IgG. Antibody showed specific staining, also of blood vessels. IHC-Fr image submitted by a verified customer review.](http://images.novusbio.com/fullsize/Vimentin-Antibody-Immunohistochemistry-Frozen-NB300-223-img0003.jpg)
![Immunohistochemistry-Frozen: Vimentin Antibody [NB300-223] - Infarcted mouse heart frozen sections stained with vimentin antibody at 1:200. Secondary antibody at 1:500. Fixation with 4% PFA. IHC-Fr image submitted by a verified customer review.](http://images.novusbio.com/fullsize/Vimentin-Antibody-Immunohistochemistry-Frozen-NB300-223-img0005.jpg)
![Immunocytochemistry/ Immunofluorescence: Vimentin Antibody [NB300-223] - Increased numbers of differentiating NSPCs in SVZ of G93A-SOD1 brain. (A) Confocal microscopy images of dorsal & ventral regions of SVZ in G93A-SOD1 & Wt-SOD1 brain at postnatal week 18, stained for nestin (green), GFAP (red), & vimentin (blue). Scale bar = 50 μm. (B) Quantification of nestin-, GFAP-, & vimentin-positive cells in SVZ of G93A-SOD1 & Wt-SOD1 mice. Data are means ± SD of 3 mice per group. **p 20 days (PyMT-1099 LT) were injected orthotopically into mammary fat pads of NSG mice. The graph represents tumor growth in PyMT-1099 & PyMT-1099 LT group of mice. (B) Histological tumor sections from tumors of PyMT-1099 or PyMT-1099 LT cells described in (A) were stained with H&E to assess the morphology of primary tumors. Representative microphotographs are shown from tumors of 2 out of the 6 mice used in the experiment. (C) Immunofluorescence analysis was performed to assess the expression of the EMT markers FN1, VIM, E-CAD & N-CAD in tumors formed by PyMT-1099 or PyMT-1099 LT cells in the experiment described in (A). DAPI was used as a nuclear counterstain. Representative pictures are shown from tumors of 2 out of the 6 mice used in the experiment. Scale bar, 100 μm. (D) The graph represents the number of lung metastases formed in NSG mice orthotopically transplanted with PyMT-1099 or PyMT-1099 LT cells; n = 6. (E) The graph represents the number of lung metastases formed in NSG mice injected with PyMT-1099 or PyMT-1099 LT cells through the tail vein; n = 6. The mice were sacrificed 8 weeks post-injection, & lungs were resected for the analysis of cancer cell colonization/ metastases formation. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/30108334), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb300-223_chicken-polyclonal-vimentin-antibody-31020241621828.jpg)
![Simple Western: beta-Actin Antibody [NB100-56874] - Image shows a specific band for Beta Actin in 1.0 mg/mL of HeLa lysate. This experiment was performed under reducing conditions using the 12-230 kDa separation system.](http://images.novusbio.com/fullsize/beta-Actin-Antibody-Simple-Western-NB100-56874-img0007.jpg "Simple Western: beta-Actin Antibody [NB100-56874] - Image shows a specific band for Beta Actin in 1.0 mg/mL of HeLa lysate. This experiment was performed under reducing conditions using the 12-230 kDa separation system.")
![Western Blot: beta-Actin Antibody [NB100-56874] - Specific bands are seen in various cell lysates at the same molecular weight. A: human brain, B: mouse brain, C: rat brain, D: human lung, and E: human spleen tissue probed using beta actin antibody at 0.25 ug/mL.](http://images.novusbio.com/fullsize/beta-Actin-Antibody-Western-Blot-NB100-56874-img0004.jpg)
![Immunocytochemistry/Immunofluorescence: beta-Actin Antibody [NB100-56874] - Actin was detected in NIH-3T3 cells fixed with methanol using rabbit anti-mouse Actin antibody (NB100-56874) at 1:100 dilution, overnight at 4C. Cells were stained using Northern Lights 557 conjugated anti-rabbit IgG secondary antibodies (NL004) and counterstained with DAPI.](http://images.novusbio.com/fullsize/beta-Actin-Antibody-Immunocytochemistry-Immunofluorescence-NB100-56874-img0009.jpg)
![Western Blot: beta-Actin Antibody [NB100-56874] - Analysis of NS5B protein expression after transfecting NS5B and La autoantigen siRNAs: HCV-infected Huh-7. 5 cells were treated with siRNAs against La autoantigen and NS5B as mentioned above. After 48h total cellular protein was isolated and subjected to western blot analysis. The analysis indicates downregulation of La autoantigen (upper gel) and NS5B (middle gel) andI2-actin (lower gel). Image collected and cropped by Citeab from the following publication (Combinations of siRNAs against La Autoantigen with NS5B or hVAP-A Have Additive Effect on Inhibition of HCV Replication. Hepat Res Treat (2016)) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/beta-Actin-Antibody-Western-Blot-NB100-56874-img0010.jpg)
![Immunohistochemistry-Paraffin: beta-Actin Antibody [NB100-56874] - Analysis of human spleen using antibody at 10 ug/mL.](http://images.novusbio.com/fullsize/beta-Actin-Antibody-Immunohistochemistry-Paraffin-NB100-56874-img0005.jpg)
![Western Blot: beta-Actin Antibody [NB100-56874] - Decreasing amounts of human ovary tissue lysate were probed using beta actin antibody at 0.25 ug/mL: A) 40 ug, B) 30 ug, C) 20 ug, D) 10 ug per lane.](http://images.novusbio.com/fullsize/beta-Actin-Antibody-Western-Blot-NB100-56874-img0003.jpg)
![Western Blot: beta-Actin Antibody [NB100-56874] - Simultaneous downregulation of multiple genes more effectively inhibits HCV replication: Huh-7.5 cells in a similar experimental setup as mentioned in Figure 1 were transfected with following combinations of siRNAs: La autoantigen + NS5B, La autoantigen + hVAP-A, La autoantigen + PSMA7, NS5B + hVAP-A, NS5B + PSMA7, & PSMA7 + hVAP-A. Downregulation of viral replication were determined by RT-PCR as shown in (a). (b) represents densitometry analysis of HCV NS5B downregulation. The data represent mean ± standard deviation. ∗P value < 0.05 versus control was considered statistically significant. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/27446609), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-56874_rabbit-polyclonal-beta-actin-antibody-310202415304250.jpg)
![Western Blot: beta-Actin Antibody [NB100-56874] - Downregulation of La autoantigen, hVAP-A, PSMA7, & NS5B leads to reduction in viral replication: overnight grown Huh-7.5 cells were transfected with La autoantigen, hVAP-A, & PSMA7 siRNAs for 48 h. Cells were then infected with the virus & again transfected with same siRNAs. After incubation total RNA was isolated & subjected to RT-PCR. NS5B siRNA was transfected once only after cells were infected. (a), (c), (e), & (g) represent RT-PCR results for target genes & NS5B gene upon treatment with La autoantigen, hVAP-A, PSMA7, & NS5B siRNAs, respectively. Densitometric analysis of (a), (c), (e), & (g) images is expressed in percentage in (b), (d), (f), & (h), respectively. The data represent mean ± standard deviation. ∗P value < 0.05 versus control considered statistically significant. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/27446609), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-56874_rabbit-polyclonal-beta-actin-antibody-310202415532081.jpg)
![Western Blot: beta-Actin Antibody [NB100-56874] - Downregulation of La autoantigen, hVAP-A, PSMA7, & NS5B leads to reduction in viral replication: overnight grown Huh-7.5 cells were transfected with La autoantigen, hVAP-A, & PSMA7 siRNAs for 48 h. Cells were then infected with the virus & again transfected with same siRNAs. After incubation total RNA was isolated & subjected to RT-PCR. NS5B siRNA was transfected once only after cells were infected. (a), (c), (e), & (g) represent RT-PCR results for target genes & NS5B gene upon treatment with La autoantigen, hVAP-A, PSMA7, & NS5B siRNAs, respectively. Densitometric analysis of (a), (c), (e), & (g) images is expressed in percentage in (b), (d), (f), & (h), respectively. The data represent mean ± standard deviation. ∗P value < 0.05 versus control considered statistically significant. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/27446609), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-56874_rabbit-polyclonal-beta-actin-antibody-31020241612664.jpg)
![Western Blot: beta-Actin Antibody [NB100-56874] - Downregulation of La autoantigen, hVAP-A, PSMA7, & NS5B leads to reduction in viral replication: overnight grown Huh-7.5 cells were transfected with La autoantigen, hVAP-A, & PSMA7 siRNAs for 48 h. Cells were then infected with the virus & again transfected with same siRNAs. After incubation total RNA was isolated & subjected to RT-PCR. NS5B siRNA was transfected once only after cells were infected. (a), (c), (e), & (g) represent RT-PCR results for target genes & NS5B gene upon treatment with La autoantigen, hVAP-A, PSMA7, & NS5B siRNAs, respectively. Densitometric analysis of (a), (c), (e), & (g) images is expressed in percentage in (b), (d), (f), & (h), respectively. The data represent mean ± standard deviation. ∗P value < 0.05 versus control considered statistically significant. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/27446609), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-56874_rabbit-polyclonal-beta-actin-antibody-310202415525271.jpg)
![Western Blot: beta-Actin Antibody [NB100-56874] - Downregulation of La autoantigen, hVAP-A, PSMA7, & NS5B leads to reduction in viral replication: overnight grown Huh-7.5 cells were transfected with La autoantigen, hVAP-A, & PSMA7 siRNAs for 48 h. Cells were then infected with the virus & again transfected with same siRNAs. After incubation total RNA was isolated & subjected to RT-PCR. NS5B siRNA was transfected once only after cells were infected. (a), (c), (e), & (g) represent RT-PCR results for target genes & NS5B gene upon treatment with La autoantigen, hVAP-A, PSMA7, & NS5B siRNAs, respectively. Densitometric analysis of (a), (c), (e), & (g) images is expressed in percentage in (b), (d), (f), & (h), respectively. The data represent mean ± standard deviation. ∗P value < 0.05 versus control considered statistically significant. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/27446609), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-56874_rabbit-polyclonal-beta-actin-antibody-310202416579.jpg)
![Western Blot: beta-Actin Antibody [NB100-56874] - Downregulation of La autoantigen, hVAP-A, PSMA7, & NS5B leads to reduction in viral replication: overnight grown Huh-7.5 cells were transfected with La autoantigen, hVAP-A, & PSMA7 siRNAs for 48 h. Cells were then infected with the virus & again transfected with same siRNAs. After incubation total RNA was isolated & subjected to RT-PCR. NS5B siRNA was transfected once only after cells were infected. (a), (c), (e), & (g) represent RT-PCR results for target genes & NS5B gene upon treatment with La autoantigen, hVAP-A, PSMA7, & NS5B siRNAs, respectively. Densitometric analysis of (a), (c), (e), & (g) images is expressed in percentage in (b), (d), (f), & (h), respectively. The data represent mean ± standard deviation. ∗P value < 0.05 versus control considered statistically significant. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/27446609), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-56874_rabbit-polyclonal-beta-actin-antibody-31020241554545.jpg)
![Western Blot: PD-L1 Antibody [NBP1-76769] - Validation with PD-L1 siRNA Knockdown. HeLa cells were transfected with control siRNAs (lane 1) or PD-L1 siRNAs (lane 2). Loading: 10 ug of HeLa whole cell lysates per lane. Antibodies: NBP1-76769 (2 ug/mL) and GAPDH (0.02 ug/mL), 1 h incubation at RT in 5% NFDM/TBST. Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution.](http://images.novusbio.com/fullsize/PD-L1-Antibody-Knockdown-Validated-NBP1-76769-img0024.jpg "<b>Genetic Strategies Validation. </b>Western Blot: PD-L1 Antibody [NBP1-76769] - Validation with PD-L1 siRNA Knockdown. HeLa cells were transfected with control siRNAs (lane 1) or PD-L1 siRNAs (lane 2). Loading: 10 ug of HeLa whole cell lysates per lane. Antibodies: NBP1-76769 (2 ug/mL) and GAPDH (0.02 ug/mL), 1 h incubation at RT in 5% NFDM/TBST. Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution.")
![<b>Independent Antibodies Validation and Genetic Strategies Validation.</b>Western Blot: PD-L1 Antibody [NBP1-76769] - Independent Antibody Validation (IAV) via Protein Expression ProfileLoading: 15 ug of lysates per lane.Antibodies: NBP1-76769 (2 ug/mL), PD-L1 (2 ug/mL), and beta-actin (1 ug/mL), 1 h incubation at RT in 5% NFDM/TBST.Secondary: Goat anti-rabbit and or anti-mouse IgG HRP conjugate at 1:10000 and 1:5000 dilution, respectively.](http://images.novusbio.com/fullsize/PD-L1-Antibody-Western-Blot-NBP1-76769-img0023.jpg)
![Immunohistochemistry-Paraffin: PD-L1 Antibody [NBP1-76769] - CD274 (PD-L1) expression in the HNSCC patients from the TCGA database , HNSCC tissue samples and the HNSCC cells. Immunostaining of PD-L1 obtained from HNSCC tumor cells, immune cells and tumor margin tissues in HNSCC tissue samples (magnification A-200, scale bars 50AI1/4m) : low tumor staining; moderate tumor staining; high tumor staining have been observed. Image collected and cropped by Citeab from the following publication (Lactoferricin B reverses cisplatin resistance in head and neck squamous cell carcinoma cells through targeting PD-L1. Cancer Med (2018)) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/PD-L1-Antibody-Immunohistochemistry-Paraffin-Negative-NBP1-76769-img0025.jpg)
![Western Blot: PD-L1 Antibody [NBP1-76769] - PD-L1 expression was evaluated in gastric cancer cells. Levels of PD-L1 protein were assessed in normal human gastric epithelial cells and 8 gastric cancer cell lines by Western blots. Image collected and cropped by Citeab from the following publication (Autophagy inhibition enhances PD-L1 expression in gastric cancer. J Exp Clin Cancer Res (2019)) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/PD-L1-Antibody-Western-Blot-NBP1-76769-img0026.jpg)
![<b>Biological Strategies Validation. </b>Western Blot: PD-L1 Antibody [NBP1-76769] - Upregulated expression of PD-L1 in cisplatin-resistant cells through IL-6/STAT3. Image collected and cropped by Citeab from the following publication (Lactoferricin B reverses cisplatin resistance in head and neck squamous cell carcinoma cells through targeting PD-L1. Cancer Med (2018)) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/PD-L1-Antibody-Western-Blot-NBP1-76769-img0027.jpg)
![Western Blot: PD-L1 Antibody [NBP1-76769] - CD274 (PD-L1) expression in the HNSCC patients from the TCGA databas HNSCC cells. CD274 expression with survival and its relation with therapy in the HNSCC patients from the TCGA database. Expression of CD274 gene and PD-L1 protein in the established cisplatin-resistant HNSCC cells and cisplatin sensitive cells by qRT-PCR and WB (F, H): CD274 (PD-L1) expressed in cisplatin resistant cell. Image collected and cropped by Citeab from the following publication (Lactoferricin B reverses cisplatin resistance in head and neck squamous cell carcinoma cells through targeting PD-L1. Cancer Med (2018)) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/PD-L1-Antibody-Western-Blot-NBP1-76769-img0028.jpg)
![Immunocytochemistry/Immunofluorescence: PD-L1 Antibody [NBP1-76769] - U-251 MG cells were fixed in 4% paraformaldehyde for 10 minutes and permeabilized in 0.05% Triton X-100 in PBS for 5 minutes. The cells were incubated with anti- NBP1-76769 at 1 ug/ml overnight at 4C and detected with an anti-rabbit Dylight 488 (Green) at a 1:1000 dilution for 60 minutes. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 100X objective and digitally deconvolved.](http://images.novusbio.com/fullsize/PD-L1-Antibody-Immunocytochemistry-Immunofluorescence-NBP1-76769-img0029.jpg)
![Flow Cytometry: PD-L1 Antibody [NBP1-76769] - An intracellular stain was performed on U-251 MG cells with PD-L1 Antibody NBP1-76769 (blue) and a matched isotype control NBP2-24891 (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 2.5 ug/mL for 30 minutes at room temperature, followed by Rabbit IgG (H+L) Cross-Adsorbed Secondary Antibody, Dylight 550 (SA5-10033, Thermo Fisher).](http://images.novusbio.com/fullsize/PD-L1-Antibody-Flow-Cytometry-NBP1-76769-img0030.jpg)
![Western Blot: PD-L1 Antibody [NBP1-76769] - Expression of CD274 in Human melanoma SK-MEL-28 cell line upon treatment with 200 mM ethanol. Dilution: 1:1,000 in PBS with 5% BSA. Secondary Ab: anti-Rabbit IgG 1:5,000. Western blot image submitted by a verified customer review.](http://images.novusbio.com/fullsize/PD-L1-Antibody-Western-Blot-NBP1-76769-img0019.jpg)
![Immunohistochemistry-Paraffin: PD-L1 Antibody [NBP1-76769] - B7-H1/PD-L1/CD274 Antibody [NBP1-76769] - Human tonsil tissue with PD-L1 antibody at 5 ug/mL.](http://images.novusbio.com/fullsize/PD-L1-Antibody-Immunohistochemistry-Paraffin-NBP1-76769-img0017.jpg)
![Immunohistochemistry-Paraffin: PD-L1 Antibody [NBP1-76769] - Staining of human heart tissue with antibody at 2.5 ug/mL.](http://images.novusbio.com/fullsize/PD-L1-Antibody-Immunohistochemistry-Paraffin-NBP1-76769-img0010.jpg)
![Immunohistochemistry-Paraffin: PD-L1 Antibody [NBP1-76769] - PD-L1/B7-H1 Antibody [NBP1-76769] - PD-L1 in rat heart tissue with at 5 ug/mL.](http://images.novusbio.com/fullsize/PD-L1-Antibody-Immunohistochemistry-Paraffin-NBP1-76769-img0020.jpg)
![Flow Cytometry: PD-L1 Antibody [NBP1-76769] - B7-H1/PD-L1/CD274 Antibody [NBP1-76769] - Analysis of A-20 cells using B7-H1/PD-L1/CD274 antibody at 0.5 ug/mL. Green: Isotype control. Red : B7-H1/PD-L1/CD274 antibody.](http://images.novusbio.com/fullsize/PD-L1-Antibody-Flow-Cytometry-NBP1-76769-img0018.jpg)
![Immunofluorescence: PD-L1 Antibody [NBP1-76769] - Human Heart cells with PD-L1 antibody at 20 ug/mL.](http://images.novusbio.com/fullsize/PD-L1-Antibody-Immunofluorescence-NBP1-76769-img0009.jpg)
![Dual RNAscope ISH-IHC: PD-L1 Antibody [NBP1-76769] - PDCD1 mRNA (red) and PD-L1 protein (green) were detected in formalin-fixed paraffin-embedded tissue sections of human lung cancer. ACD's Integrated Co-Detection Workflow was performed using ACD RNAScope Probe Hs-PDCD1 and PD-L1 antibody at 1:100 dilution. Tissue was stained on Leica Bond RX using RNAscope (TM) 2.5 LS Reagent Kit-RED, BOND Polymer Refine Detection (DAB) and Hematoxylin, BOND Polymer Refine Red Detection and Hematoxylin and RNAscope (TM) 2.5 LS Green Accessory Pack. Tissue was counterstained with 50% hematoxylin (blue).](http://images.novusbio.com/fullsize/PD-L1-Antibody-Dual-RNAscope-ISH-IHC-NBP1-76769-img0031.jpg)
![Western Blot: PD-L1 Antibody - BSA Free [NBP1-76769] - ROS mediated PD-L1 upregulation in FFA-treated LO2 cells. (a) Intracellular ROS in LO2 cells before & after FFA treatment measured by DCFH-DA. (b–d) Expression levels of NOX2 & NOX4 measured using qRT-PCR & western blot. (e) JC-1 probes were used to detect mitochondrial membrane potential. (f–j) Intracellular ROS in LO2 cells pretreated with siRNA against NOX4, MitoTEMPO (10 μM), or NAC (5 mM) followed by FFA treatment, measured by DCFH-DA, PD-L1 expression determined by western blot. ∗∗P < 0.01. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/35615575), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-76769_rabbit-polyclonal-pd-l1-antibody-310202415382415.jpg)
![Western Blot: PD-L1 Antibody - BSA Free [NBP1-76769] - Inhibition of NF-kappa B or STAT3 downregulated PD-L1 expression in adi-CM model. a PD-L1 protein levels in HepG2 cells treated with different concentration of NF-kappa B inhibitor, withaferin A (WA). b PD-L1 protein levels in HepG2 cells treated with different concentration of STAT3 inhibitor, BP-1-102. c PD-L1 protein levels in B16-F1 cells incubated with WA. Data are expressed as mean ± SEM, n = 6, **P < 0.01, ***P < 0.001 Vs adi-CM group. ##P < 0.01 & ###P < 0.001 Vs DMSO group Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/32477009), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-76769_rabbit-polyclonal-pd-l1-antibody-31020241534538.jpg)
![Western Blot: PD-L1 Antibody - BSA Free [NBP1-76769] - PD-L1 expression levels in liver samples & FFA-treated LO2 cells. (a–d) PD-L1 expression & CD8+ T cells in the liver tissues determined by immunohistochemistry. (e) Intracellular lipid accumulation after FFA treatment (0.8 mM) for 24 hour measured by Oil Red staining. (f–i) Expression levels of PD-L1 detected by qRT-PCR, western blot, & immunofluorescence. ∗∗P < 0.01. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/35615575), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-76769_rabbit-polyclonal-pd-l1-antibody-310202415175299.jpg)
![Western Blot: PD-L1 Antibody - BSA Free [NBP1-76769] - Inhibition of NF-kappa B or STAT3 downregulated PD-L1 expression in adi-CM model. a PD-L1 protein levels in HepG2 cells treated with different concentration of NF-kappa B inhibitor, withaferin A (WA). b PD-L1 protein levels in HepG2 cells treated with different concentration of STAT3 inhibitor, BP-1-102. c PD-L1 protein levels in B16-F1 cells incubated with WA. Data are expressed as mean ± SEM, n = 6, **P < 0.01, ***P < 0.001 Vs adi-CM group. ##P < 0.01 & ###P < 0.001 Vs DMSO group Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/32477009), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-76769_rabbit-polyclonal-pd-l1-antibody-310202415291978.jpg)
![Western Blot: PD-L1 Antibody - BSA Free [NBP1-76769] - Inhibition of NF-kappa B or STAT3 downregulated PD-L1 expression in adi-CM model. a PD-L1 protein levels in HepG2 cells treated with different concentration of NF-kappa B inhibitor, withaferin A (WA). b PD-L1 protein levels in HepG2 cells treated with different concentration of STAT3 inhibitor, BP-1-102. c PD-L1 protein levels in B16-F1 cells incubated with WA. Data are expressed as mean ± SEM, n = 6, **P < 0.01, ***P < 0.001 Vs adi-CM group. ##P < 0.01 & ###P < 0.001 Vs DMSO group Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/32477009), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-76769_rabbit-polyclonal-pd-l1-antibody-310202415175210.jpg)
![Western Blot: PD-L1 Antibody - BSA Free [NBP1-76769] - ROS/ZNF24/PD-L1 pathway activation in NAFLD models. (a) Intracellular ROS in hepatocytes in NAFLD significantly increased. (b) JC-1 probes were used to detect mitochondrial membrane potential. (c & d) NOX4 & ZNF24 expressions were determined by immunohistochemistry. (e & f) ROS/ZNF24/PD-L1 pathway activation examined by western blot. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/35615575), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-76769_rabbit-polyclonal-pd-l1-antibody-310202415284517.jpg)
![Western Blot: PD-L1 Antibody - BSA Free [NBP1-76769] - PD-L1 limits liver injury in NAFLD models. (a & b) Western blot determined the effect of siRNA against PD-L1. (c) After PD-L1 knockdown, mRNA expression levels of markers of T cell activation measured by qRT-PCR. (d & e) Hepatocyte injury was evaluated by the Tunel assay & ALT/AST measurement. (f) Graph illustrating that both ROS/ZNF24 pathway activation & UBE2I-mediated ZNF24 sumoylation suppression induced by FFA promoted PD-L1 expression. ∗P < 0.05, ∗∗P < 0.01. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/35615575), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-76769_rabbit-polyclonal-pd-l1-antibody-31020241529331.jpg)
![Western Blot: PD-L1 Antibody - BSA Free [NBP1-76769] - PD-L1 knockdown aggravated the damage of CD8 + T cells to FFA-treated LO2 cells. (a & b) Western blot determined the effect of siRNA against PD-L1. Coculturing of FFA-treated LO2 cells & CD8 + T cells in vitro. (c) mRNA expression levels of markers of T cell activation measured by qRT-PCR, (d) LO2 cell injury was evaluated by LDH assay, (e) AST or ALT in the supernatants measured by commercial assay kits. # represents that CD8 + T cells were incubated separately with LO2 cells, but supernatants were put together. ∗P < 0.05, ∗∗P < 0.01. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/35615575), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-76769_rabbit-polyclonal-pd-l1-antibody-310202415304228.jpg)
![Western Blot: PD-L1 Antibody - BSA Free [NBP1-76769] - Upregulated expression of PD‐L1 in cisplatin‐resistant cells through IL‐6/STAT3. The cisplatin resistant CAL27cis & Detroit‐562cis cells had increased IL‐6 mRNA & IL‐6 protein production compared to parental cells by qRT‐PCR & ELISA (A, B). CAL27cis & Detroit‐562cis were cultured with IL‐6 (10 ng/mL, human recombinant IL‐6, R&D Systems, Minneapolis, USA) for 48 h (C). An anti‐human IL‐6 polyclonal antibody (R&D Systems, Minneapolis, USA) was used to neutralize the biological activities of IL‐6 (E, F). To inhibit signal transduction, CAL27cis & Detroit‐562cis cells were pre‐incubated for 1 h with STAT3 inhibitor V (Sigma‐Aldrich, Germany, 500 nmol/L), & then incubated with recombinant human IL‐6 (10 ng/mL) for 24 h before analysis. Data are shown as mean ± SD of 3 independent triplicate cultures (A, B, D, E, F, H). *P < .05, **P < .01 & ***P < .001, compared with the results of control without IL‐6 (D), control IgG (E, F) & with IL‐6 alone (H) Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/29761938), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-76769_rabbit-polyclonal-pd-l1-antibody-310202416175266.jpg)
![Western Blot: PD-L1 Antibody - BSA Free [NBP1-76769] - ZNF24 promoted PD-L1 expression through binding to its promoter in FFA-treated LO2 cells. (a) A schematic of the target sites (wild & mutant) of ZNF24 in the promoter of PD-L1. (b–d) Dual-luciferase reporter assays performed in LO2 cells transfected with WT or MT plasmid containing ZNF24-binding sites in the PD-L1 promoter using Lipofectamine 2000 after ZNF24 overexpression. (e–g) ZNF24 expression after FFA treatment determined by qRT-PCR & western blot. (h & i) ZNF24 expression in LO2 cells pretreated with siRNA against NOX4, MitoTEMPO (10 μM), or NAC (5 mM) followed by FFA treatment, measured by western blot. (j & k) ZNF24 & PD-L1 expression in LO2 cells pretreated with siRNA against ZNF24, followed by FFA treatment detected by western blot. ∗∗P < 0.01. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/35615575), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-76769_rabbit-polyclonal-pd-l1-antibody-310202416165623.jpg)
![Western Blot: PD-L1 Antibody - BSA Free [NBP1-76769] - LfcinB reduced IL‐6‐dependent PD‐L1 expression in cisplatin‐resistant HNSCC cells (A‐C) & inhibited the xenograft growth from CAL27cis & Detroit‐562cis (D, E). The markedly decreased IL‐6 (A) by ELISA & PD‐L1 by WB (B, C) in the acquired cisplatin‐resistant cells were detected. In figure A, C & D, data are shown as mean ± SD of 3 independent triplicate cultures. *P < .05 & **P < .01, compared with the results of control without IL‐6 (A, C). To investigate the effects of LfcinB on in vivo growth of CAL27cis & Detroit‐562cis, we treated nude mice carrying CAL27cis (D) & Detroit‐562cis (E) xenografts with once‐daily injection of 0.75 mg LfcinB (n = 5). Tumor growth of HNSCC xenografts displayed significant reduction after 3 days of LfcinB treatment, compared to control with saline (*P < .05 for LfcinB) Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/29761938), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-76769_rabbit-polyclonal-pd-l1-antibody-310202416175227.jpg)
![Western Blot: PD-L1 Antibody - BSA Free [NBP1-76769] - Identification of ZNF24–UBE2I protein interactions. (a & b) Analysis of protein interactions between ZNF24 & UBE2I using the BioGRID database, further confirmed by Co-IP assays. (c–f) UBE2I expression in LO2 cells treated by FFA or pretreated with siRNA against NOX4, MitoTEMPO (10 μM), or NAC (5 mM) followed by FFA treatment measured by western blot. (g & h) After FFA treatment, Sumo-1: ZNF24 & ZNF24 expression levels detected by western blot. (i & j) After UBE2I overexpression, Sumo-1: ZNF24, ZNF24, PD-L1, & UBE2I expression levels were determined by western blot. (k–m) Dual-luciferase reporter assays performed in LO2 cells transfected with WT plasmid containing ZNF24-binding sites in the PD-L1 promoter using Lipofectamine 2000 after ZNF24 overexpression with or without Sumo-1 overexpression. ∗∗P < 0.01. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/35615575), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-76769_rabbit-polyclonal-pd-l1-antibody-310202416175269.jpg)
![Western Blot: Collagen I alpha 1 Antibody - Azide and BSA Free [NBP1-30054] - Collagen I Antibody [NBP1-30054] - Rat lung lysate showing specific immunolabeling of the collagen protein with an observed molecular weight ~140.](http://images.novusbio.com/fullsize/Collagen-I-alpha-1-Antibody---Azide-and-BSA-Free-Western-Blot-NBP1-30054-img0005.jpg "Western Blot: Collagen I alpha 1 Antibody - Azide and BSA Free [NBP1-30054] - Collagen I Antibody [NBP1-30054] - Rat lung lysate showing specific immunolabeling of the collagen protein with an observed molecular weight ~140.")
![Immunohistochemistry: Collagen I alpha 1 Antibody - Azide and BSA Free [NBP1-30054] - Immunohistochemical staining targeting Collagen I alpha 1 revealed severe disorganization of the annulus fibrosus (AF), and a decrease in staining intensity for group D. On the contrary, the arcshaped and layered AF structure with immunoreactivity for type I collagen staining were mostly maintained in group S when compared to group C. Presented images show the AF at site of surgery, defect, and transplant. Abbreviations: D: AF defect only group, S: AF defect treated with sheet transplantation group, C: sham group, NC: negative control of sample stained without primary antibody (scale bar=300um). Image collected and cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31463464/) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/Collagen-I-alpha-1-Antibody---Azide-and-BSA-Free-Immunohistochemistry-NBP1-30054-img0006.jpg)
![Immunohistochemistry: Collagen I alpha 1 Antibody - Azide and BSA Free [NBP1-30054] - Collagen I Antibody [NBP1-30054] - Formaldehyde-fixed fibrotic mouse lung tissue. The antibody recognizes mature collagen I (red) that has formed fibrils in the extracellular matrix.](http://images.novusbio.com/fullsize/Collagen-I-alpha-1-Antibody---Azide-and-BSA-Free-Immunohistochemistry-NBP1-30054-img0004.jpg)
![Simple Western: Collagen I alpha 1 Antibody - Azide and BSA Free [NBP1-30054] - Simple Western lane view shows a specific band for Collagen I Alpha 1 in 0.5 mg/ml of Human Lung (left) and Human Kidney (right) lysate. This experiment was performed under reducing conditions using the 66-440 kDa separation system. * Non-specific interaction with the 230 kDa Simple Western standard may be seen with this antibody](http://images.novusbio.com/fullsize/Collagen-I-alpha-1-Antibody---Azide-and-BSA-Free-Simple-Western-NBP1-30054-img0003.jpg)
![Western Blot: Collagen I alpha 1 Antibody - Azide and BSA Free [NBP1-30054] - TNC deficiency reduced kidney fibrosis in animal models.Deletion of TNC (TNC−/−) significantly attenuated the induction of collagen I assessed by IF following UUO by approximate 30% at day 7 & 10 compared with their wild-type littermates (A, n = 4 for each time point, two-way ANOVA p < 0.05). Consistently, the expression of fibrosis markers, such as collagen I alpha , fibronectin & plasminogen activator inhibitor-1 (PAI-1), were significantly lower in TNC−/− mice at UUO day 7 & 10 (B, n = 4 for each time point, two-way ANOVA, p < 0.05). Western blot showed that the proteins of collagen I alpha & alpha -SMA were also significantly reduced in TNC−/− mice at UUO day 7 (C, n = 7, p < 0.05). Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/36522320), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-30054_rabbit-polyclonal-collagen-i-alpha-1-antibody-31020241534311.jpg)
![Western Blot: Glut1 Antibody [NB110-39113] - PrP-mediated increase in IC iron downregulates glucose transporters in the brain, neuroretina, and the liver: A similar evaluation of retinal lysates shows upregulation of Glut1 in PrP-/- relative to Tg40 PrP samples (lanes 1 & 3). Iron overloading downregulates Glut1 in Tg40 PrP samples relative to untreated controls, but has minimal effect on similarly treated PrP-/- samples (lanes 2 & 4). Image collected and cropped by CiteAb from the following publication (//www.nature.com/articles/s41598-018-24786-1) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/Glut1-Antibody-Western-Blot-NB110-39113-img0019.jpg "<b>Biological Strategies Validation. </b>Western Blot: Glut1 Antibody [NB110-39113] - PrP-mediated increase in IC iron downregulates glucose transporters in the brain, neuroretina, and the liver: A similar evaluation of retinal lysates shows upregulation of Glut1 in PrP-/- relative to Tg40 PrP samples (lanes 1 & 3). Iron overloading downregulates Glut1 in Tg40 PrP samples relative to untreated controls, but has minimal effect on similarly treated PrP-/- samples (lanes 2 & 4). Image collected and cropped by CiteAb from the following publication (//www.nature.com/articles/s41598-018-24786-1) licensed under a CC-BY license.")
![<b>Biological Strategies Validation. </b>Western Blot: Glut1 Antibody [NB110-39113] - Western blot of GLUT1 on mouse kidney membrane protein (lane A) and rat kidney membrane protein (lane B).](http://images.novusbio.com/fullsize/Glut1-Antibody-Western-Blot-NB110-39113-img0006.jpg)
![Immunohistochemistry-Paraffin: Glut1 Antibody [NB110-39113] - Immunohistochemical analysis of FFPE tissue section of human placenta using 1:200 dilution of Glut1 antibody. The staining was developed using HRP-DAB detection method and the sections were further counterstained with hematoxylin. This antibody generated a specific strong membrane cytoplasmic staining of Glut1 primarily in the syncytiotrophoblast layers of various villi and in the red blood cells (RBCs). Cytotrophoblasts showed a very weak expression of this protein.](http://images.novusbio.com/fullsize/Glut1-Antibody-Immunohistochemistry-Paraffin-NB110-39113-img0011.jpg)
![Flow Cytometry: Glut1 Antibody [NB110-39113] - An intracellular stain was performed on HepG2 with NB110-39113 and a matched isotype control. Cells were fixed with 4% PFA and then permeablized with 0.1% saponin. Cells were incubated in an antibody dilution of 5 ug/mL for 30 minutes at room temperature, followed by Rabbit IgG (H+L) Cross-Adsorbed Secondary Antibody.](http://images.novusbio.com/fullsize/Glut1-Antibody-Flow-Cytometry-NB110-39113-img0018.jpg)
![Immunocytochemistry/Immunofluorescence: Glut1 Antibody [NB110-39113] - HepG2 cells were fixed for 10 minutes using 10% formalin and then permeabilized for 5 minutes using 1X TBS + 0.5% Triton X-100. The cells were incubated with anti-GLUT1 at a 1:200 dilution overnight at 4C and detected with an anti-rabbit DyLight 488 (Green) at a 1:500 dilution. Alpha tubulin (DM1A) NB100-690 was used as a co-stain at a 1:1000 dilution and detected with an anti-mouse DyLight 550 (Red) at a 1:500 dilution. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 40X objective](http://images.novusbio.com/fullsize/Glut1-Antibody-Immunocytochemistry-Immunofluorescence-NB110-39113-img0013.jpg)
![Western Blot: Glut1 Antibody [NB110-39113] - Analysis of HeLa lysates using NB110-39113. Image courtesy of Gregg Semenza (PMID: 21620138).](http://images.novusbio.com/fullsize/Glut1-Antibody-Western-Blot-NB110-39113-img0007.jpg)
![Western Blot: Glut1 Antibody [NB110-39113] - Glut1 in human brain lysate (55 kDa). Antibody at 1:500. Western blot image submitted by a verified customer review.](http://images.novusbio.com/fullsize/Glut1-Antibody-Western-Blot-NB110-39113-img0016.jpg)
![<b>Biological Strategies Validation. </b>Flow Cytometry: Glut1 Antibody [NB110-39113] - Flow cytometry analysis using the PE conjugate of NB110-39113. Staining of Glut 1 expression on CD4+ T cells stimulated with anti-CD3/CD28 beads and insulin (1ug/mL) for 5 days in culture media with additional glucose provided. FMO control (red) and isotype control (blue, NBP2-24983) were compared to CD4+ T cells (orange), and this PE conjugated Glut 1 antibody positively stained CD4+ lymphocytes isolated from Mouse. Flow cytometry image submitted by a verified customer review.](http://images.novusbio.com/fullsize/Glut1-Antibody-Flow-Cytometry-NB110-39113-img0014.jpg)
![Immunocytochemistry/ Immunofluorescence: Glut1 Antibody - BSA Free [NB110-39113] - LAIR-1 inhibits Glut1-related glucose uptake in OS cells. a Heatmap showing the levels of differentially expressed mRNAs. b Top 20 KEGG pathway annotation categories for target gene functions of predicted mRNAs. c Selected significantly differentially expressed mRNA-related to EMT in RNA-seq data between two groups, ***P < 0.001. d qPCR validation of differentially expressed EMT-related genes in LV-NC & LV-LAIR-1-overexpressing OS cells, **P < 0.01. e Glut1 expression analyzed by western blotting. f Immunofluorescence staining of Glut1 in the LV-LAIR-1-overexpressing OS cells. Scale bar = 50 μm. Data were obtained from at least two independent experiments. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/32563267), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb110-39113_rabbit-polyclonal-glut1-antibody-310202415175286.jpg)
![Western Blot: Glut1 Antibody - BSA Free [NB110-39113] - LAIR-1 inhibits Glut1-related glucose uptake in OS cells. a Heatmap showing the levels of differentially expressed mRNAs. b Top 20 KEGG pathway annotation categories for target gene functions of predicted mRNAs. c Selected significantly differentially expressed mRNA-related to EMT in RNA-seq data between two groups, ***P < 0.001. d qPCR validation of differentially expressed EMT-related genes in LV-NC & LV-LAIR-1-overexpressing OS cells, **P < 0.01. e Glut1 expression analyzed by western blotting. f Immunofluorescence staining of Glut1 in the LV-LAIR-1-overexpressing OS cells. Scale bar = 50 μm. Data were obtained from at least two independent experiments. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/32563267), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb110-39113_rabbit-polyclonal-glut1-antibody-310202415334922.jpg)
![Simple Western: Glut1 Antibody - BSA Free [NB110-39113] - Protein changes in ONHAs corroborate bioenergetics data. (A) Glucose transporter-1 protein levels in Stretched ONH astrocytes are significantly higher than Control (*p = 0.0225, n = 7 Control, n = 8 Stretch). Retinal lysate from a 2 month-old mouse was used as a positive control for each protein analyzed, while negative control was the signal obtained when no primary antibody was included in the capillary. (B) Lactate dehydrogenase-A, the astrocyte-specific isoform of the enzyme that catalyzes the interconversion of pyruvate & lactate, has equivalent protein levels in Control & Stretch ONH astrocytes. (C) Glucose-6-phosphate dehydrogenase, the enzyme that shunts glucose into the pentose phosphate pathway, is no different in Control & Stretch ONH astrocytes. (D) Glutamine synthetase, the enzyme that synthesizes glutamine from glutamate, is no different in Control & Stretch ONH astrocytes. (E) The monomeric form of glutamate-aspartate transporter (GLAST) has significantly higher protein levels in the Stretch as compared to the Control ONH astrocytes (p = 0.020; n = 4 Control, n = 5 Stretch). (F) GLAST dimer protein levels are no different in Control & Stretch ONH astrocytes. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/35992925), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb110-39113_rabbit-polyclonal-glut1-antibody-310202416284917.jpg)
![Flow Cytometry: Cytokeratin, pan Antibody (AE-1/AE-3) [NBP2-29429] - An intracellular stain was performed on HeLa cells with pan Cytokeratin Antibody (AE1 + AE3) NBP2-33200AF647 (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 5 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to Alexa Fluor 647. Image from the AF647 version of this antibody.](http://images.novusbio.com/fullsize/nbp2-29429_mouse-monoclonal-cytokeratin-pan-antibody-ae-1-ae-3-imgenex-nbo-135a-20ug-17720249362612.jpg)
![Flow Cytometry: Cytokeratin, pan Antibody (AE-1/AE-3) [NBP2-29429] - An intracellular stain was performed on HeLa cells with pan Cytokeratin [AE1 + AE3] Antibody NBP2-33200AF488 (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 5 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to Alexa Fluor 488. Image from the AF488 version of this antibody.](http://images.novusbio.com/fullsize/nbp2-29429_mouse-monoclonal-cytokeratin-pan-antibody-ae-1-ae-3-imgenex-nbo-135a-20ug-17720241003217.jpg)
![Flow Cytometry: Cytokeratin, pan Antibody (AE-1/AE-3) [NBP2-29429] - An intracellular stain was performed on HeLa cells with pan Cytokeratin Antibody (AE1 + AE3) NBP2-33200PE (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 2.5 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to phycoerythrin. Image from the PE version of this antibody.](http://images.novusbio.com/fullsize/nbp2-29429_mouse-monoclonal-cytokeratin-pan-antibody-ae-1-ae-3-imgenex-nbo-135a-20ug-1772024944230.jpg)
![Western Blot: Noxa Antibody (114C307.1R) [NBP3-07012] - Doc counteracts the ABT-737-mediated increase in Mcl-1 protein. Western blot showing treatment of LNCaP and PC3 cells with 1 uM ABT-737. In LNCaP and PC3, there are few difference in Noxa. Image collected and cropped by CiteAb from the following publication (//peerj.com/articles/144), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/Noxa-Antibody-114C307-1R-Western-Blot-NBP3-07012-img0003.jpg "Western Blot: Noxa Antibody (114C307.1R) [NBP3-07012] - Doc counteracts the ABT-737-mediated increase in Mcl-1 protein. Western blot showing treatment of LNCaP and PC3 cells with 1 uM ABT-737. In LNCaP and PC3, there are few difference in Noxa. Image collected and cropped by CiteAb from the following publication (//peerj.com/articles/144), licensed under a CC-BY license.")
![Immunocytochemistry/Immunofluorescence: Noxa Antibody (114C307.1R) [NBP3-07012] - ICC/IF analysis using the azide-free version of NB600-1159 at 1:10. HeLa cells with DyLight 488 (green). Nuclei and alpha-tubulin were counterstained with DAPI (blue) and DyLight 550 (red). Image objective 40X.](http://images.novusbio.com/fullsize/Noxa-Antibody-114C307-1R-Immunocytochemistry-Immunofluorescence-NBP3-07012-img0004.jpg)
![Flow Cytometry: Noxa Antibody (114C307.1R) [NBP3-07012] - An intracellular stain was performed on Ntera2 cells with Noxa Antibody [114C307.1R] NBP3-07012 (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 1.0 ug/mL for 30 minutes at room temperature, followed by Mouse IgG (H+L) Cross-Adsorbed Secondary Antibody, Dylight 550 (35503, Thermo Fisher).](http://images.novusbio.com/fullsize/Noxa-Antibody-114C307-1R-Flow-Cytometry-NBP3-07012-img0002.jpg)
![Immunocytochemistry/Immunofluorescence: Noxa Antibody (114C307.1R) [NBP3-07012] - HeLa cells were fixed in 4% paraformaldehyde for 10 minutes and permeabilized in 0.05% Triton X-100 in PBS for 5 minutes. The cells were incubated with anti-Noxa Antibody (114C307.1R) NBP3-07012 at 2 ug/ml overnight at 4C and detected with an anti-mouse Dylight 488 (Green) at a 1:1000 dilution for 60 minutes. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 100X objective and digitally deconvolved.](http://images.novusbio.com/fullsize/Noxa-Antibody-114C307-1R-Immunocytochemistry-Immunofluorescence-NBP3-07012-img0001.jpg)
![Immunohistochemistry-Paraffin: Noxa Antibody (114C307.1R) - BSA Free [NBP3-07012] - Immunohistochemical analysis of bouin-fixed, paraffin-embedded chronic lymphocytic leukemia (CLL) xenograft stained with Noxa antibody (1:2000), peroxidase-conjugate and DAB chromogen. Staining for 2 hr at RT was used.](http://images.novusbio.com/fullsize/nbp3-07012_mouse-monoclonal-noxa-antibody-114c307-1r-1772024104467.jpg)
![Western Blot: Noxa Antibody (114C307.1R) - BSA Free [NBP3-07012] - Detection by Western blot in RL-7 cells (a follicular lymphoma).](http://images.novusbio.com/fullsize/nbp3-07012_mouse-monoclonal-noxa-antibody-114c307-1r-1772024959411.jpg)
![Flow Cytometry: Noxa Antibody (114C307.1R) - BSA Free [NBP3-07012] - Flow cytometry after an intracellular stain was performed on MCF7 cells with Noxa [114C307.1] antibody NB600-1159AF700 (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 5 ug/mL for 30 minutes at room temperature. Both antibodies were directly conjugated to Alexa Fluor 700.](http://images.novusbio.com/fullsize/nbp3-07012_mouse-monoclonal-noxa-antibody-114c307-1r-1772024959421.jpg)
![Flow Cytometry: Noxa Antibody (114C307.1R) - BSA Free [NBP3-07012] - Flow cytometry after an intracellular stain was performed on HeLa cells with Noxa [114C307.1] antibody NB600-1159AF700 (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 5 ug/mL for 30 minutes at room temperature. Both antibodies were directly conjugated to Alexa Fluor 700.](http://images.novusbio.com/fullsize/nbp3-07012_mouse-monoclonal-noxa-antibody-114c307-1r-17720249362613.jpg)
![Western Blot: alpha-Smooth Muscle Actin Antibody [NB300-978] - (1ug/ml) staining of Mouse Duodenum lysate (35ug protein in RIPA buffer). Detected by chemiluminescence.](http://images.novusbio.com/fullsize/alpha-Smooth-Muscle-Actin-Antibody-Western-Blot-NB300-978-img0007.jpg "Western Blot: alpha-Smooth Muscle Actin Antibody [NB300-978] - (1ug/ml) staining of Mouse Duodenum lysate (35ug protein in RIPA buffer). Detected by chemiluminescence.")
![Immunocytochemistry/Immunofluorescence: alpha-Smooth Muscle Actin Antibody [NB300-978] - SMA antibody staining on mouse fibroblasts. Primary antibody at 1:1000, incubation at 4C overnight. ICC/IF image submitted by a verified customer review.](http://images.novusbio.com/fullsize/alpha-Smooth-Muscle-Actin-Antibody-Immunocytochemistry-Immunofluorescence-NB300-978-img0006.jpg)
![Immunohistochemistry-Frozen: alpha-Smooth Muscle Actin Antibody [NB300-978] - Infarcted mouse heart frozen tissue section immunostained with alpha-Smooth Muscle Actin Antibody. IHC-Fr image submitted by a verified customer review.](http://images.novusbio.com/fullsize/alpha-Smooth-Muscle-Actin-Antibody-Immunohistochemistry-Frozen-NB300-978-img0003.jpg)
![alpha-Smooth Muscle Actin Antibody [NB300-978] - (1ug/ml) staining of HeLa (A) and (2ug/ml) NIH3T3 (B) cell lysate (35ug protein in RIPA buffer). Detected by chemiluminescence.](http://images.novusbio.com/fullsize/alpha-Smooth-Muscle-Actin-Antibody-NB300-978-img0008.jpg)
![Immunohistochemistry-Paraffin: Goat Polyclonal alpha-Smooth Muscle Actin Antibody [NB300-978] - Analysis of alpha-Smooth Muscle Actin Antibody on mouse heart tissue. Image from a verified customer review.](http://images.novusbio.com/fullsize/antibody/nb300-978_goat-polyclonal-alpha-smooth-muscle-actin-antibody-immunohistochemistry-paraffin-61202594652..jpg)
![Simple Western: beta-Actin Antibody [NB600-532] - Simple Western lane view shows a specific band for Beta Actin using NB600-532 at 1:200 in A431, C2C12 and C6 cell lysates. This experiment was performed under reducing conditions using the 12-230 kDa separation system.](http://images.novusbio.com/fullsize/beta-Actin-Antibody-Simple-Western-NB600-532-img0016.jpg "Simple Western: beta-Actin Antibody [NB600-532] - Simple Western lane view shows a specific band for Beta Actin using NB600-532 at 1:200 in A431, C2C12 and C6 cell lysates. This experiment was performed under reducing conditions using the 12-230 kDa separation system.")
![Western Blot: beta-Actin Antibody [NB600-532] - Detection of actin in 3T3 lysates (20ug). ECL detection 30 seconds. A specific band is seen using different dilutions: Lane 1 (1:15,000), Lane 2 (1:10,000), and Lane 3 (1:15,000).](http://images.novusbio.com/fullsize/beta-Actin-Antibody-Western-Blot-NB600-532-img0009.jpg)
![Western Blot: beta-Actin Antibody [NB600-532] - Detection of human and mouse Cytoskeletal Actin by western blot. Samples: Whole cell lysate (50 ug) from HeLa, HEK293T, Jurkat, mouse TCMK-1, and mouse NIH 3T3 cells prepared using NETN lysis buffer. Antibody: Affinity purified rabbit anti-Cytoskeletal Actin antibody NB600-532 used for WB at 0.1 ug/ml. Detection: Chemiluminescence with an exposure time of 1 second.](http://images.novusbio.com/fullsize/beta-Actin-Antibody-Western-Blot-NB600-532-img0014.jpg)
![Western Blot: beta-Actin Antibody [NB600-532] - Mouse colon whole cell lysate. PVDF membrane was probed with Rabbit Anti-B actin Antibody (Catalog # NB600-532) followed by HRP-conjugated Anti-Rabbit IgG Secondary Antibody. WB image submitted by a verified customer review.](http://images.novusbio.com/fullsize/beta-Actin-Antibody-Western-Blot-NB600-532-img0019.jpg)
![Immunohistochemistry: beta-Actin Antibody [NB600-532] - Detection of human Cytoskeletal Actin by immunohistochemistry. Sample: FFPE section of human ovarian cancer. Antibody: Affinity purified rabbit anti-Cytoskeletal Actin (NB600-532). Detection: DAB](http://images.novusbio.com/fullsize/beta-Actin-Antibody-Immunohistochemistry-NB600-532-img0015.jpg)
![Western Blot: beta-Actin Antibody [NB600-532] - Western blot analysis of Actin (NB600-532) using RCC4 whole cell lysate [NBP1-30412].](http://images.novusbio.com/fullsize/beta-Actin-Antibody-Western-Blot-NB600-532-img0006.jpg)
![Western Blot: beta-Actin Antibody [NB600-532] - Western blot analysis of Actin (NB600-532) using HepG2 whole cell lysate [NBP1-42569].](http://images.novusbio.com/fullsize/beta-Actin-Antibody-Western-Blot-NB600-532-img0007.jpg)
![Western Blot: beta-Actin Antibody [NB600-532] - Analysis using the HRP conjugate of NB600-532. Detection of Beta Actin in MCF-7 cell lysate (20ug) using anti-Beta Actin antibody. WB image submitted by a verified customer review.](http://images.novusbio.com/fullsize/beta-Actin-Antibody-Western-Blot-NB600-532-img0011.jpg)
![Western Blot: beta-Actin Antibody [NB600-532] - Treatments of periplocin and/or TRAIL activate DR4, FADD, and proapoptotic proteins in HCC cells. The effect of periplocin treatment on the expression of DR4, DR5, and FADD was analyzed by western blot. Image collected and cropped by CiteAb from the following publication (//www.hindawi.com/journals/ecam/2013/958025/), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/beta-Actin-Antibody-Western-Blot-NB600-532-img0018.jpg)
![Western Blot: beta-Actin Antibody [NB600-532] - Hypoxic preconditioning increases PBMNC sensitivity to apelin-13 via upregulation of APJ expression, leading to growth factor secretion.(a) APJ protein expression was significantly increased in hypoxic PBMNCs. *p <0.05 vs. N-PBMNCs. Image collected and cropped by CiteAb from the following publication (//www.nature.com/articles/srep19379), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/beta-Actin-Antibody-Western-Blot-NB600-532-img0017.jpg)
![Immunohistochemistry: beta-Actin Antibody [NB600-532] - Sample: FFPE section of human lung carcinoma. Antibody: Affinity purified rabbit anti-Cytoskeletal Actin used at a dilution of 1:1,000 (1ug/ml). Detection: DAB](http://images.novusbio.com/fullsize/beta-Actin-Antibody-Immunohistochemistry-NB600-532-img0012.jpg)
![Western Blot: beta-Actin Antibody [NB600-532] - Cotreatment of periplocin & TRAIL activated IAP. (a) The expression levels of Bax, Bad, Mcl-1, apaf-1, & caspase 9 in HA22T/VGH in response to 1 μM periplocin and/or 100 ng/mL TRAIL treatment were examined by western blot. (b) The expression levels of Bcl-2, cIAP-1, cIAP-2, XIAP, & survivin in HA22T/VGH in response to 1 μM periplocin and/or 100 ng/mL TRAIL treatment were examined by western blot. The original blots are shown in supplemental Figure 2. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/23365613), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb600-532_rabbit-polyclonal-beta-actin-antibody-310202415284538.jpg)
![Western Blot: beta-Actin Antibody [NB600-532] - Treatments of periplocin and/or TRAIL activate DR4, FADD, & proapoptotic proteins in HCC cells. (a) The effect of periplocin treatment on the expression of DR4, DR5, & FADD was analyzed by western blot. (b) HA22T/VGH cells were treated with different doses of the indicated compounds for 24 h. Expressions of both proforms & cleaved forms of caspase-8, caspase 3, PARP, & BID were analyzed by western blotting. (c) Huh-7 cells were treated with different concentrations of the indicated compounds for 4 h or 24 h. The expression of caspase-8, caspase-9 was analyzed after indicated compounds treatment for 4 h, & the expression of caspase 3, PARP, BID was analyzed after the treatment of indicated compounds for 24 h. (d) HA22T/VGH cells were pretreated with 20 μM or 50 μM inhibitors against caspase-3 (Z-DEVD-FMK), caspasae-8 (Z-IETD-FMK), caspase-9 (Z-LEHD-FMK), & general caspase inhibitor (Z-VAD-FMK) for 3 hours prior to periplocin and/or TRAIL treatment. Cell viability was examined by MTT assay. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/23365613), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb600-532_rabbit-polyclonal-beta-actin-antibody-310202416182625.jpg)
![Western Blot: beta-Actin Antibody [NB600-532] - GRN PTC readthrough rescues FTLD/NCL lysosomal pathological CSTD maturation phenotype in hiPSC-derived R493X−/− KI cortical neurons. a DIV 80 WT & R493X−/− KI hiPSC-derived cortical neurons were treated with vehicle solution, G418 alone, G418 in combination with CDX5–288, & rec. Human PGRN at the indicated concentrations for 72 h. Expression of mature CSTD in treated WT & R493X−/− KI cortical neuron lysates analyzed by western blotting, using actin as the loading control. b Densitometric quantification of CSTD expression in the aforementioned cortical neuron lysates normalized to vehicle-treated WT levels. n = 3–6 independent cultures; values are shown as mean ± SEM; * p < 0.05, ** p < 0.01, was determined by one-way ANOVA with Tukey’s multiple comparison test Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/32178712), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb600-532_rabbit-polyclonal-beta-actin-antibody-31020241618923.jpg)
![Western Blot: beta-Actin Antibody [NB600-532] - Induction of PTC readthrough by G418 & enhancers in hiPSC-derived R493X−/− KI astrocytes. a R493X−/− KI hiPSC-derived astrocytes were treated with vehicle solution, G418 alone, G418 in combination with CDX5–288, & rec. Human PGRN at the indicated concentrations for 72 h. Expression of PGRN & GRN-2,3 peptides in treated WT & R493X−/− KI astrocyte samples were analyzed by western blotting, using actin as the loading control. b Densitometric quantification of ~ 70 kDa PGRN (i) & GRN-2,3 peptide (ii) in astrocyte lysates (a) normalized to vehicle-treated (VT) WT levels. VT WT was excluded from ii due to oversaturation of GRN-2,3 signal in long exposure blot. For clarity, rec. Human PGRN treated R493X−/− KI astrocytes expressed 20.9% ± 0.027 of VT WT GRN-2,3 levels based on quantification of the short exposure blot (data not shown). c R493X−/− KI hiPSC-derived astrocytes were treated with vehicle solution, G418 in combination with CDX5–288, & G418 CDX5–288 combination with either 10 or 30 μM of Z-Phe-Phe-FMK for 72 h. Again, expression of PGRN in WT & R493X−/− KI astrocyte lysates was also analyzed by western blotting, using actin as the loading control. d Densitometric quantification of full-length PGRN in astrocyte lysates (c) normalized to VT WT levels. n = 3 independent cultures (except in dn = 2); values are shown as mean ± SEM; p < 0.05, ** p < 0.01, *** p < 0.0001 was determined by one-way ANOVA with Tukey’s multiple comparison test Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/32178712), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb600-532_rabbit-polyclonal-beta-actin-antibody-310202416163749.jpg)
![Simple Western: beta-Actin Antibody [NB600-532] - Induction of PTC readthrough by G418 & CDX5 enhancers in cells expressing GRN-V5. a Schematic of full-length PGRN highlighting the position of the S116X (UAA), R418X (UGA), & R493X (UGA) nonsense mutations in relation to the position of individual granulin peptides & the C-terminal V5 tag. b HEK293 cell lines stably expressing GRN-V5 with the indicated nonsense mutations were treated with G418 & the indicated concentrations of CDX5–1, CDX5–196, & CDX5–288 for 72 h. Cell culture supernatants (extracellular) & cell lysates (intracellular) were subjected to automated capillary electrophoresis western analysis. Full-length PGRN was detected with a V5 antibody. Actin was measured in cell lysates as a loading control. The readthrough enhancement ratios are indicated under the lanes. The proportion loaded was 15–20 fold lower for the extracellular samples than for the intracellular samples Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/32178712), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb600-532_rabbit-polyclonal-beta-actin-antibody-310202416173532.jpg)
![Immunohistochemistry-Frozen: Collagen I alpha 1 Antibody (COL-1) [NB600-450] - Staining of acetone-fixed, frozen sections of pig tongue at a dilution of 1:4000](http://images.novusbio.com/fullsize/Collagen-I-alpha-1-Antibody-COL-1-Immunohistochemistry-Frozen-NB600-450-img0003.jpg "Immunohistochemistry-Frozen: Collagen I alpha 1 Antibody (COL-1) [NB600-450] - Staining of acetone-fixed, frozen sections of pig tongue at a dilution of 1:4000")
![Immunohistochemistry: Collagen I alpha 1 Antibody (COL-1) [NB600-450] - Analysis of an FFPE ligament section. Enzymatic antigen retrieval and blocking using 1% BSA for 30 min at 20C was performed. Sample was incubated for 1 hour with primary antibody at a dilution of 1:400 at 20C.](http://images.novusbio.com/fullsize/Collagen-I-alpha-1-Antibody-COL-1-Immunohistochemistry-NB600-450-img0006.jpg)
![Immunocytochemistry/Immunofluorescence: Collagen I alpha 1 Antibody (COL-1) [NB600-450] - Collagen I and collagen III accumulate in C57BL/6 mice in response to radiation. Bladder strips from irradiated and control mice were stained for collagen I or for collagen III (NB600-594, RRID:AB_10001330) and imaged using fluorescent microscopy. Representative images (100 x 100 um) of each mouse strain and treatment group are provided for collagen I and collagen III immunofluorescence. Image collected and cropped by CiteAb from the following publication (www.onlinelibrary.wiley.com/doi/abs/10.14814/phy2.14377) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/Collagen-I-alpha-1-Antibody-COL-1-Immunocytochemistry-Immunofluorescence-NB600-450-img0014.jpg)
![Immunohistochemistry: Collagen I alpha 1 Antibody (COL-1) [NB600-450] - Staining of acetone-fixed, frozen sections of human tongue at a dilution of 1:2000.](http://images.novusbio.com/fullsize/Collagen-I-alpha-1-Antibody-COL-1-Immunohistochemistry-NB600-450-img0017.jpg)
![Immunocytochemistry/Immunofluorescence: Collagen I alpha 1 Antibody (COL-1) [NB600-450] - Analysis of Collagen I alpha 1 in 4% PFA fixed equine tenocytes using anti-Collagen I alpha 1 antibody. ICC/IF image submitted by a verified customer review.](http://images.novusbio.com/fullsize/Collagen-I-alpha-1-Antibody-COL-1-Immunocytochemistry-Immunofluorescence-NB600-450-img0010.jpg)
![Immunocytochemistry/Immunofluorescence: Collagen I alpha 1 Antibody (COL-1) [NB600-450] - Collagen I alpha1 labeled pig trabecular meshwork cells indirectly visualized with Alexa Fluor 488 conjugated secondary antibody. ICC/IF image submitted by a verified customer review.](http://images.novusbio.com/fullsize/Collagen-I-alpha-1-Antibody-COL-1-Immunocytochemistry-Immunofluorescence-NB600-450-img0012.jpg)
![Immunohistochemistry: Collagen I alpha 1 Antibody (COL-1) [NB600-450] - Analysis of formalin fixed frozen porcine skin tissue sections. Blocking: 5% serum for 1 hr at 20C. Sample was incubated for 16 hours at 4C and used at a dilution of 1:500.](http://images.novusbio.com/fullsize/Collagen-I-alpha-1-Antibody-COL-1-Immunohistochemistry-NB600-450-img0008.jpg)
![Immunohistochemistry: Collagen I alpha 1 Antibody (COL-1) [NB600-450] - Immunohistochemistry for type I collagen in keloid (20x). Image collected and cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/28638180/) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/Collagen-I-alpha-1-Antibody-COL-1-Immunohistochemistry-NB600-450-img0013.jpg)
![Immunohistochemistry-Paraffin: Collagen I alpha 1 Antibody (COL-1) [NB600-450] - Mouse healthy liver. Anibody at 1:200. Enzymatic/proteolytic antigen retrieval. No permeabilization. IHC-P image submitted by a verified customer review.](http://images.novusbio.com/fullsize/Collagen-I-alpha-1-Antibody-COL-1-Immunohistochemistry-Paraffin-NB600-450-img0015.jpg)
![Immunohistochemistry: Collagen I alpha 1 Antibody (COL-1) [NB600-450] - FSP‐1–positive cells only partially responsible for collagen I & III production in irradiated bladders. Bladder strips from irradiated mice were costained for collagen I or for collagen III mRNA (pink) & for fibroblasts (FSP‐1, brown). U: urothelium; LP: lamina propria. Black arrow: FSP‐1 positive cells. Gray arrow: collagen only positive cells. Scale bar = 50 µm Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/32109348), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb600-450_mouse-monoclonal-collagen-i-alpha-1-antibody-col-1-310202415175218.jpg)
![Western Blot: Cytochrome c Antibody (7H8.2C12) [NB100-56503] - Metformin activates apoptotic cell death; Right panel: MCF-7 cells were kept in the presence or absence of metformin for 20 days and then processed to obtain mitochondrial or whole cellular extracts. BAX and CYCS expression levels were determined by Western blot as indicated under Material and Methods. Densitometric analysis of the gels was performed as indicated under Material and Methods. PHB and CDK4 were used as purity and loading controls. Image collected and cropped by CiteAb from the following publication (//www.mdpi.com/2073-4409/8/1/49), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/Cytochrome-c-Antibody-7H8-2C12-Western-Blot-NB100-56503-img0015.jpg "<b>Biological Strategies Validation. </b>Western Blot: Cytochrome c Antibody (7H8.2C12) [NB100-56503] - Metformin activates apoptotic cell death; Right panel: MCF-7 cells were kept in the presence or absence of metformin for 20 days and then processed to obtain mitochondrial or whole cellular extracts. BAX and CYCS expression levels were determined by Western blot as indicated under Material and Methods. Densitometric analysis of the gels was performed as indicated under Material and Methods. PHB and CDK4 were used as purity and loading controls. Image collected and cropped by CiteAb from the following publication (//www.mdpi.com/2073-4409/8/1/49), licensed under a CC-BY license.")
![<b>Biological Strategies Validation. </b>Immunocytochemistry/Immunofluorescence: Cytochrome c Antibody (7H8.2C12) [NB100-56503] - p73 was detected in immersion fixed Hela human cell line using NB100-56503 at 25 ug/ml for 3 hours at room temperature. Cells were stained using the NorthernLights(TM) 557-conjugated Anti-Mouse IgG Secondary Antibody (red; Catalog # NL007) and counterstained with DAPI (blue). Staining was observed in the cytoplasm and mitochondria.](http://images.novusbio.com/fullsize/Cytochrome-c-Antibody-7H8-2C12-Immunocytochemistry-Immunofluorescence-NB100-56503-img0010.jpg)
![Immunohistochemistry-Paraffin: Cytochrome c Antibody (7H8.2C12) [NB100-56503] - Cytochrome C was detected in immersion fixed paraffin-embedded sections of human heart using anti-human mouse monoclonal antibody (Catalog # NB100-56503) at 1:200 dilution overnight at 4C. Tissue was stained using the VisuCyte anti-mouse HRP polymer detection reagent (Catalog # VC001) with DAB chromogen (brown) and counterstained with hematoxylin (blue).Images may not be copied, printed or otherwise disseminated without express written permission of Novus Biologicals a bio-techne brand.](http://images.novusbio.com/fullsize/Cytochrome-c-Antibody-7H8-2C12-Immunohistochemistry-Paraffin-NB100-56503-img0004.jpg)
![Flow (Intracellular): Cytochrome c Antibody (7H8.2C12) [NB100-56503] - An intracellular stain was performed on HeLa cells with Cytochrome c (7H8.2C12) antibody NB100-56503PE (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeablized with 0.1% saponin. Cells were incubated in an antibody dilution of 5 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to phycoerythrin.](http://images.novusbio.com/fullsize/Cytochrome-c-Antibody-7H8-2C12-Flow-Intracellular-NB100-56503-img0014.jpg)
![Western Blot: Cytochrome c Antibody (7H8.2C12) [NB100-56503] - Human HeLa lysate probed with Cytochrome C antibody at 0.1 ug/ml.](http://images.novusbio.com/fullsize/Cytochrome-c-Antibody-7H8-2C12-Western-Blot-NB100-56503-img0001.jpg)
![Western Blot: Cytochrome c Antibody (7H8.2C12) [NB100-56503] - Analysis using the biotin conjugate of NB100-56503. Detection of Cytochrome C in 15 ug of HeLa cell lysate using NB100-55775 at 1:1000. A 15 kDa band is detected.](http://images.novusbio.com/fullsize/Cytochrome-c-Antibody-7H8-2C12-Western-Blot-NB100-56503-img0003.jpg)
![Flow Cytometry: Cytochrome c Antibody (7H8.2C12) [NB100-56503] - Detection of Cytochrome C in Human HeLa Cell Line by Flow Cytometry. Human HeLa cell line was stained with Mouse Anti- Cytochrome C Monoclonal Antibody (Catalog # NB100-56503, filled histogram), or Mouse IgG2B isotype control (Catalog # MAB0041, open histogram) followed by APC-conjugated Anti-Mouse IgG Secondary Antibody (Catalog # F0101B). To facilitate intracellular staining, cells were fixed with Flow Cytometry Fixation Buffer (Catalog # FC004) and permeabilized with Flow Cytometry Permeabilization/Wash Buffer I (Catalog # FC005).Images may not be copied, printed or otherwise disseminated without express written permission of Novus Biologicals a bio-techne brand.](http://images.novusbio.com/fullsize/Cytochrome-c-Antibody-7H8-2C12-Flow-Cytometry-NB100-56503-img0005.jpg)
![Flow Cytometry: Cytochrome c Antibody (7H8.2C12) [NB100-56503] - Using the Alexa Fluor 488 direct conjugate, an intracellular stain was performed on HeLa cells with Cytochrome c (7H8.2C12) antibody NB100-56503AF488 (blue) and a matched isotype control NBP2-27231AF488 (orange). Cells were fixed with 4% PFA and then permeablized with 0.1% saponin. Cells were incubated in an antibody dilution of 10 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to Alexa Fluor 488.](http://images.novusbio.com/fullsize/Cytochrome-c-Antibody-7H8-2C12-Flow-Cytometry-NB100-56503-img0011.jpg)
![Simple Western: Cytochrome c Antibody (7H8.2C12) [NB100-56503] - Lane view shows lysates of human heart tissue, loaded at 0.2 mg/mL. A specific band was detected for Cytochrome c at approximately 23 kDa (as indicated) using 2.5 ug/mL of Mouse Anti-Cytochrome c Monoclonal Antibody (Catalog # NB100-56503). This experiment was conducted under reducing conditions and using the 12-230 kDa separation system.](http://images.novusbio.com/fullsize/Cytochrome-c-Antibody-7H8-2C12-Simple-Western-NB100-56503-img0013.jpg)
![Simple Western: Cytochrome c Antibody (7H8.2C12) [NB100-56503] - Cytochrome C Antibodies (NB100-56503SS), ProteinSimple Western Blot on Jess Instrument; 1 microgram of human brain tissue lysate was tested with the antibodies diluted 20 times. Image from verified customer review.](http://images.novusbio.com/fullsize/antibody/nb100-56503_mouse-monoclonal-cytochrome-c-antibody-7h8-2c12-imgenex-img-101a-simple-western-204202312023.jpg)
